The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.
about
Statistical Methods for Establishing Personalized Treatment Rules in OncologyAnalysis of time to event outcomes in randomized controlled trials by generalized additive modelsLifetime alcohol use and overall and cause-specific mortality in the European Prospective Investigation into Cancer and nutrition (EPIC) studyCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Survival analysis of time-to-event data in respiratory health research studies.Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataDifference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study.Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.Evaluating surrogate marker information using censored data.Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.Extrapolating Survival from Randomized Trials Using External Data: A Review of MethodsMoving beyond the hazard ratio in quantifying the between-group difference in survival analysis.Evaluation of rapid progressors in HIV infection as an extreme phenotype.Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.Bias and precision of measures of survival gain from right-censored data.Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.Time-dependent ROC curve analysis in medical research: current methods and applications.Can Internet-Based Sexual Health Services Increase Diagnoses of Sexually Transmitted Infections (STI)? Protocol for a Randomized Evaluation of an Internet-Based STI Testing and Results ServiceA predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studiesAn EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530).Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models.Predicting the restricted mean event time with the subject's baseline covariates in survival analysis.Targeted temperature management in cardiac arrest: survival evaluated by propensity score matching.Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models.Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.Restricted mean survival time over 15 years for patients starting renal replacement therapy.Integrating genomic signatures for treatment selection with Bayesian predictive failure time models.Household food security and breast-feeding duration among Canadian Inuit.Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients.Estimation of time-shift models with application to survival calibration in health technology assessment.Parametric multistate survival models: Flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences.On the restricted mean survival time curve in survival analysisA versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies.Prognostic Value of Braden Activity Subscale for Mobility Status in Hospitalized Older Adults.Clinical characteristics and advantages of primary peripheral micro-sized lung adenocarcinoma over small-sized lung adenocarcinoma.Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.Synthetic sickness or lethality points at candidate combination therapy targets in glioblastoma.An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
P2860
Q26786366-46503066-2012-47E2-90DE-CD0DF1A23F41Q27309297-7A30F61D-B3BC-4F7A-845F-757587438866Q28655880-634CE359-5255-4B0E-8620-FEE635104BD6Q30521133-C0DCA523-5823-46F1-B736-7A8E15A5D525Q30790979-281758FE-948D-4C8D-A555-376864414340Q30976026-23F6691E-3300-4E44-A044-300353BE851AQ31036587-210BD557-045F-40D7-BD39-60242A8B61C3Q31056094-69CDC7CB-B392-4459-891B-E8BC840DB63DQ31064714-3132DC5D-45D9-4F33-8266-FA8D46C51534Q31154746-F4BF87DD-F9DD-425C-9B88-CA96B4BE03CDQ33434899-0D74024E-3DB7-4ECD-AC7A-510D8E12F4CFQ33654108-430BC78C-1865-4529-9A95-FC7D0BFD50EBQ33928010-5381B9B3-1227-441E-BB5F-2478B0A86466Q34051108-ACF52DAF-593B-4736-ADF1-4E7C6C97B2CFQ35061982-F86CB208-9147-4C9D-9A1E-04DE62FD240CQ35720400-37C732DA-3B6E-4727-A99F-A4F3ACA84367Q35921629-CB01342D-0CF3-4023-BD03-5A2CA1460E16Q36340398-C618ED4F-D8FA-4EF2-AC96-560F612CC4F2Q36521418-6040F5D2-F5F9-44A7-A15E-31CA01C18C1EQ37026562-736A7AC6-ECC4-4DB9-8B3E-48744C0DD9F9Q37357076-FAD06D47-DD58-404D-BC38-2E61A75D103AQ37558401-8F3D8E68-C45B-4B3C-8F17-0B7832BB0EC2Q37621905-CBB2C047-540B-490A-8988-8AFBE41DE3C5Q37708306-75DFC494-5CBA-4F61-B800-03A850B00713Q38662083-EE28F264-87DB-4DDF-9AA1-06F6BD9E85ACQ38722045-D074F0EA-3FE7-4021-AEF4-B9697FA19623Q39037219-86D2F1D0-0C4D-4017-A0A6-05DD95434FA2Q39222626-726EE488-40DA-4B1B-9343-8A6556C04F4BQ39553067-111468CE-C559-4861-B70D-2B08EA9557EEQ39647659-942D64A2-E197-4069-B570-5843686127F0Q39870168-AD872D25-7187-498D-8E2E-855F169F316AQ40057652-7F31B275-1008-403D-A119-ABF4963A60C3Q40612925-FE27431E-374A-428E-84DD-5C2EF7BB278DQ40714930-7E75436C-581A-4ABE-ABFB-185E7B19DA09Q40858704-AB924CAB-FD85-44FD-82A0-C55A62FCFD02Q41343301-FE1C942C-1A8D-4C75-B16F-C4966F06D0FFQ41353981-82DD32DA-D1F9-4D43-81CC-B4F301FDF518Q42245812-AA36167C-3B06-4B3B-89EA-E391BC61BCE7Q42597215-FCCD8D5F-FD7F-44C2-B747-446DD4C44679Q42792001-C0E63419-C5FF-42DF-8FA7-0FD66CAFBB40
P2860
The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
The use of restricted mean sur ...... azards assumption is in doubt.
@en
The use of restricted mean sur ...... azards assumption is in doubt.
@nl
type
label
The use of restricted mean sur ...... azards assumption is in doubt.
@en
The use of restricted mean sur ...... azards assumption is in doubt.
@nl
prefLabel
The use of restricted mean sur ...... azards assumption is in doubt.
@en
The use of restricted mean sur ...... azards assumption is in doubt.
@nl
P2860
P356
P1476
The use of restricted mean sur ...... azards assumption is in doubt.
@en
P2093
Mahesh K B Parmar
P2860
P304
P356
10.1002/SIM.4274
P407
P577
2011-05-25T00:00:00Z